ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION

Clinical trials for ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION explained in plain language.

Never miss a new study

Get alerted when new ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION trials appear

Sign up with your email to follow new studies for ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Could a targeted drug keep AML in check?

Disease control Completed

This phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…

Matched conditions: ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION

Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Jun 27, 2026 14:02 UTC

ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION

Get alerted when new ADULT ACUTE MYELOID LEUKEMIA WITH MINIMAL DIFFERENTIATION trials appear

Could a targeted drug keep AML in check?